STTDAAProject ID: 661441
Financé au titre de:
Synthesis of Truncated Tirandamycin A-D Derivatives as new Antihelminthic Agents
Détails concernant le projet
Coût total:EUR 173 857,20
Contribution de l'UE:EUR 173 857,20
Appel à propositions:H2020-MSCA-IF-2014See other projects for this call
Régime de financement:MSCA-IF-EF-ST - Standard EF
This project entitled “Synthesis of Truncated tirandamycin A-D derivatives as new Antihelminthic Agents (STTDAA)” aims at developing novel asparaginyl tRNA synthetase (AsnRS) inhibitors as potential antihelminthic agents, with new mechanisms of action for potential treatment of lymphatic filariasis (LF).
LF is one of the World Health Organization’s (WHO) top 10 neglected tropical diseases (NTDs), This incapacitating disease has infected over 200 million people in 73 tropical and subtropical countries, while more than 1.4 billion people remain at the risk of infection. Thus a top priority of the WHO is to search for new antihelminthic drugs that kill adult worms (macrofilaricides), have new mechanisms of action, and exhibit fewer side effects than currently available medications such as albendazole and ivermectin to which parasite resistance has already been confirmed.
To this end, two distinctively different but complimentary synthetic approaches towards tirandamycin A-D (TAMs A-D) derivatives, as AsnRS inhibitors will be developed. This will be followed by intensive structure activity relationship (SAR) studies, which will further promote improvements of the bioactivity and the drug characteristic of the synthesized derivatives. These studies will compose a vital part of a more comprehensive drug development program.
Contribution de l'UE: EUR 173 857,20
405 30 GOETEBORG